News and updates
BioMérieux Serology Testing for SARS-CoV-2 on VIDAS® undergo validation preceding the imminent launch
VIDAS® Anti SARS-CoV-2 IgM and Anti-SARS-CoV-2 IgG
BioMérieux, a world leader in the field of in-vitro diagnostics, on May 06, 2020 – announced performance validation and the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to the SARS-CoV-2 that causes the COVID-19 disease.
• VIDAS® Anti SARS-CoV-2 IgM and Anti-SARS-CoV-2 IgG will identify in less than 30 minutes the presence of antibodies in people who have been infected with SARS-CoV-2
• Hospitals and private laboratories can run the tests on bioMérieux’s VIDAS® analyzers (MINI VIDAS® & VIDAS®) which are widely available with more than 30,000 systems installed around the world.
BioMérieux aims to have the VIDAS® anti-SARS-CoV-2 serology tests available by mid-May as RUO (Research Use Only). They will be CE marked rapidly thereafter and bioMérieux will file a request for Emergency Use Authorization (EUA) to the US Food and Drug Administration.
